Severe acute neurological symptoms related to proton pump inhibitors induced hypomagnesemia responsible for profound hypoparathyroidism with hypocalcemia

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 5, 2014, Pages e103-e105

  Deroux, Alban ^a   Khouri, Charles ^a   Chabre, Olivier ^a   Bouillet, Laurence ^a   Casez, Olivier ^a  

^a GRENOBLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CREATINE KINASE; MAGNESIUM; OMEPRAZOLE; PARATHYROID HORMONE; POTASSIUM; PROTON PUMP INHIBITOR; TROPONIN;

ADULT; AGED; AMNESIA; APHASIA; BLOOD SAMPLING; BRAIN CORTEX; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CASE REPORT; CLONUS; CONFUSION; DISEASE SEVERITY; DRUG WITHDRAWAL; DYSPEPSIA; FACIAL NERVE; FEMALE; FOCAL EPILEPSY; GASTROESOPHAGEAL REFLUX; HUMAN; HYPERTENSION; HYPOCALCEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOPARATHYROIDISM; LETTER; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MEDICAL HISTORY; MINERAL SUPPLEMENTATION; MUSCLE CONTRACTURE; MUSCLE SPASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PARESTHESIA; PHYSICAL EXAMINATION; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; TETANY; TREATMENT DURATION; ACUTE DISEASE; CHEMICALLY INDUCED; COMPLICATION; METABOLIC DISORDER; METABOLISM; NERVOUS SYSTEM DISEASES; SEVERITY OF ILLNESS INDEX;

ACUTE DISEASE; ADULT; AGED; FEMALE; HUMANS; HYPOCALCEMIA; HYPOPARATHYROIDISM; MAGNESIUM; METABOLIC DISEASES; NERVOUS SYSTEM DISEASES; PROTON PUMP INHIBITORS; SEVERITY OF ILLNESS INDEX;

EID: 84912527272     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.03.005     Document Type: Letter

References (18)

1. Seelig M.S. Magnesium deficiency in the pathogenesis of disease 1980, Plenum Medical Book Co, New York, Part 3, chapter 12.
2. Rude R.K., Oldham S.B., Singer F.R. Functional hypoparathyroidism and parathyroid hormone end-organ resistance in human magnesium deficiency. Clin Endocrinol (Oxf) 1976, 5(3):209-224.
3. Fellenius E., Berglindh T., Sachs G., Olbe L., Elander B., Sjostrand S.E., et al. Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+K+)ATPase. Nature 1981, 290(5802):159-161.
4. Heidelbaugh J.J., Inadomi J.M. Magnitude and economic impact of inappropriate use of stress ulcer prophylaxis in non-ICU hospitalized patients. Am J Gastroenterol 2006, 101:2200-2205.
5. Johnson D.A., Oldfield E.C. Reported side effects and complications of long-term Proton Pump Inhibitor use: dissecting the evidence. Clin Gastroenterol Hepatol 2013, 11:458-464.
6. Food Drug Association FDA Drug Safety Podcast for Healthcare Professionals: low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs) [Internet] 2014, Available on: http://www.fda.gov/Drugs/DrugSafety/DrugSafetyPodcasts/ucm245455.html (Accessed 17January 2014).
7. Epstein M., Mc Grath S., Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med 2006, 355:1834-1836.
8. Agus Z.S. Hypomagnesemia. J Am Soc Nephrol 1999, 10:1616-1622.
9. Rude R.K. Magnesium deficiency: a cause of heterogenous disease in humans. J Bone Miner Res 1998, 13:749-758.
10. Al-Ghamdi S.M., Cameron E.C., Sutton R.A. Magnesium deficiency: pathophysiologic and clinical overview. Am J Kidney Dis 2004, 24:737-752.
11. Mackay J.D., Bladon P.T. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM 2010, 103:387-395.
12. Song Y., Hsu Y.H., Niu T., Manson J.E., Buring J.E., Liu S. Common genetic variants of the ion channel transient receptor potential membrane melastatin 6 and 7 (TRPM6 and TRPM7), magnesium intake, and risk of type 2 diabetes in women. BMC Med Genet 2009, 10:4.
13. Hess M.W., Hoenderop J.G.J., Bindels R.J.M., Drenth J.P.H. Systematic review: hypomagnesaemia induced by proton pump inhibition. Aliment Pharmacol Ther 2012, 36(5):405-413.
14. Furlanetto T.W. Hypomagnesemia and proton pump inhibitors; below the tip of the iceberg. Arch Intern Med 2011, 171(15):1391.
15. Famularo G., Gasbarrone L., Minisola G. Hypomagnesemia and proton-pump inhibitors. Expert Opin Drug Saf 2013, 12(5):709-716.
16. Hoom E.J., Van Der Hoek J., De Man R.A., Kuipers E.J., Bolwerk C., Zietse R. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis 2010, 56(1):112-116.
17. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981, 30(2):239-245.
18. Danziger J., William J.H., Scott D.J., Lee J., Lehman L.W., Mark R.G., et al. Proton-pump inhibitor use is associated with low serum magnesium concentrations. Kidney Int 2013, 83:682-699.